Recall Jujitsu: Can FDA’s Alert Shortcomings Help It Politically?
Research in the Archives of Internal Medicine suggests FDA doesn’t always notify the public about serious drug recalls as well as it should. But the agency is using the findings to emphasize how much firms could be doing as the debate on the design of a distribution tracking system swirls on Capitol Hill.
You may also be interested in...
House and Senate avoided some contentious issues when passing their user fee bills, leaving them to an informal conference committee to work out, ideally before the end of June.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.